drugset / Trial / NCT00390312

Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction

NCT00390312

Phase 2 Completed 225 enrolled Javelin Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study involves approximately 200 patients designed to evaluate the efficacy and safety of intranasal (IN) morphine 7.5 mg and 15 mg, intravenous morphine (IV) 7.5 mg, immediate release oral (PO) morphine 60 mg or placebo in patients with acute postsurgical pain following third molar extraction.

Timeline

Start
2001-09
Primary completion
2001-11
Completion
2001-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified 7.5 mg Intranasal
Subject Morphine Other / unclassified 15 mg Intranasal
Subject Morphine Other / unclassified 60 mg Intranasal

Indications

No indication recorded.